Exploiting tumor epigenetics to improve oncolytic virotherapy
Oncolytic viruses (OVs) comprise a versatile and multi-mechanistic therapeutic platform in the growing arsenal of anticancer biologics. These replicating therapeutics find favorable conditions in the tumor niche, characterized among others by increased metabolism, reduced anti-tumor/antiviral immuni...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2013-09-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fgene.2013.00184/full |
| _version_ | 1811277642188455936 |
|---|---|
| author | Nicole E. Forbes Nicole E. Forbes Hesham eAbdelbary Hesham eAbdelbary Mathieu eLupien Mathieu eLupien John C. Bell John C. Bell Jean-Simon eDiallo Jean-Simon eDiallo |
| author_facet | Nicole E. Forbes Nicole E. Forbes Hesham eAbdelbary Hesham eAbdelbary Mathieu eLupien Mathieu eLupien John C. Bell John C. Bell Jean-Simon eDiallo Jean-Simon eDiallo |
| author_sort | Nicole E. Forbes |
| collection | DOAJ |
| description | Oncolytic viruses (OVs) comprise a versatile and multi-mechanistic therapeutic platform in the growing arsenal of anticancer biologics. These replicating therapeutics find favorable conditions in the tumor niche, characterized among others by increased metabolism, reduced anti-tumor/antiviral immunity, and disorganized vasculature. Through a self-amplification that is dependent on multiple cancer-specific defects, these agents exhibit remarkable tumor selectivity. With several OVs completing or entering Phase III clinical evaluation, their therapeutic potential as well as the challenges ahead are increasingly clear. One key hurdle is tumor heterogeneity, which results in variations in the ability of tumors to support productive infection by OVs and to induce adaptive anti-tumor immunity. To this end, mounting evidence suggests tumor epigenetics may play a key role. This review will focus on the epigenetic landscape of tumors and how it relates to OV infection. Therapeutic strategies aiming to exploit the epigenetic identity of tumors in order to improve OV therapy are also discussed. |
| first_indexed | 2024-04-13T00:20:33Z |
| format | Article |
| id | doaj.art-b70aa544e2a64ae1aa92ddab1e4193ac |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-13T00:20:33Z |
| publishDate | 2013-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-b70aa544e2a64ae1aa92ddab1e4193ac2022-12-22T03:10:47ZengFrontiers Media S.A.Frontiers in Genetics1664-80212013-09-01410.3389/fgene.2013.0018455401Exploiting tumor epigenetics to improve oncolytic virotherapyNicole E. Forbes0Nicole E. Forbes1Hesham eAbdelbary2Hesham eAbdelbary3Mathieu eLupien4Mathieu eLupien5John C. Bell6John C. Bell7Jean-Simon eDiallo8Jean-Simon eDiallo9Ottawa Hospital Research InstituteUniversity of OttawaOttawa Hospital Research InstituteUniversity of OttawaOntario Cancer Institute, Princess Margaret Cancer Center/University Health NetworkOntario Institute for Cancer ResearchOttawa Hospital Research InstituteUniversity of OttawaOttawa Hospital Research InstituteUniversity of OttawaOncolytic viruses (OVs) comprise a versatile and multi-mechanistic therapeutic platform in the growing arsenal of anticancer biologics. These replicating therapeutics find favorable conditions in the tumor niche, characterized among others by increased metabolism, reduced anti-tumor/antiviral immunity, and disorganized vasculature. Through a self-amplification that is dependent on multiple cancer-specific defects, these agents exhibit remarkable tumor selectivity. With several OVs completing or entering Phase III clinical evaluation, their therapeutic potential as well as the challenges ahead are increasingly clear. One key hurdle is tumor heterogeneity, which results in variations in the ability of tumors to support productive infection by OVs and to induce adaptive anti-tumor immunity. To this end, mounting evidence suggests tumor epigenetics may play a key role. This review will focus on the epigenetic landscape of tumors and how it relates to OV infection. Therapeutic strategies aiming to exploit the epigenetic identity of tumors in order to improve OV therapy are also discussed.http://journal.frontiersin.org/Journal/10.3389/fgene.2013.00184/fullAntigen PresentationOncolytic VirotherapyCancertumor heterogeneityEpigenetic ModulationAnti-Viral Response |
| spellingShingle | Nicole E. Forbes Nicole E. Forbes Hesham eAbdelbary Hesham eAbdelbary Mathieu eLupien Mathieu eLupien John C. Bell John C. Bell Jean-Simon eDiallo Jean-Simon eDiallo Exploiting tumor epigenetics to improve oncolytic virotherapy Frontiers in Genetics Antigen Presentation Oncolytic Virotherapy Cancer tumor heterogeneity Epigenetic Modulation Anti-Viral Response |
| title | Exploiting tumor epigenetics to improve oncolytic virotherapy |
| title_full | Exploiting tumor epigenetics to improve oncolytic virotherapy |
| title_fullStr | Exploiting tumor epigenetics to improve oncolytic virotherapy |
| title_full_unstemmed | Exploiting tumor epigenetics to improve oncolytic virotherapy |
| title_short | Exploiting tumor epigenetics to improve oncolytic virotherapy |
| title_sort | exploiting tumor epigenetics to improve oncolytic virotherapy |
| topic | Antigen Presentation Oncolytic Virotherapy Cancer tumor heterogeneity Epigenetic Modulation Anti-Viral Response |
| url | http://journal.frontiersin.org/Journal/10.3389/fgene.2013.00184/full |
| work_keys_str_mv | AT nicoleeforbes exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT nicoleeforbes exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT heshameabdelbary exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT heshameabdelbary exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT mathieuelupien exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT mathieuelupien exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT johncbell exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT johncbell exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT jeansimonediallo exploitingtumorepigeneticstoimproveoncolyticvirotherapy AT jeansimonediallo exploitingtumorepigeneticstoimproveoncolyticvirotherapy |